Depemokimab

5 trials 2 recruiting

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

3 Completed trials

1 Sponsors

19 Countries

Phase III

Phase III: 5

Indications tested

Asthma 1 Hypereosinophilic syndrome 1 Eosinophilic granulomatosis with polyangiitis 1

Sponsors using this IMP

Glaxosmithkline Research & Development Limited 5

All trials

5 total

A phase 3b study of depemokimab on airway structure and function in patients with type 2 asthma utilizing quantitative high-resolution CT an… Recruiting

2024-519976-19-00 Phase III 6 countries Glaxosmithkline Research & Development Limited
A study to Investigate the efficacy and safety of Depemokimab compared with placebo in Adults with Hypereosinophilic Syndrome (HES) Recruiting

2023-510346-25-00 Phase III 9 countries Glaxosmithkline Research & Development Limited
A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic … Ended

2023-510019-20-00 Phase III 11 countries Glaxosmithkline Research & Development Limited
A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended

2023-505203-23-01 Phase III 7 countries Glaxosmithkline Research & Development Limited
Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin… Ended

2023-510230-84-00 Phase III 12 countries Glaxosmithkline Research & Development Limited

Showing 1–5 of 5 trials

← All drugs A–Z